Cencora stock after-hours at EUR 54.63: plus 0.11 percent versus prior close
Published on 09/30/2026 at 21:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cencora stock was at EUR 54.63 after-hours at 9:02 p.m. CEST on September 30, 2026, up 0.11 percent versus the prior close of EUR 54.57 at Lang & Schwarz.
Cencora stock after the Xetra close
The Lang & Schwarz quote was EUR 0.06 above the prior close. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Cencora stock.
Board appointment takes effect October 1
Cencora announced that its board elected Robert E. Sanchez as an independent director, effective October 1, 2026. The company said Sanchez is executive chair of Ryder System and previously served as that company’s chair and chief executive officer. Cencora’s board chair Mark Durcan and Chief Executive Officer Robert P. Mauch cited Sanchez’s public-company, logistics, supply-chain, operations, finance and technology experience.
New cell and gene therapy service
In a September 2, 2026 release, Cencora said its Accelerate Pharmacy Solutions unit launched Cell and Gene Therapy Enablement. The service is intended to help health systems evaluate, build and scale programs, with support covering financial assessments, operational readiness, governance design, workflow planning and scalable operating models.
